# Nuclide record lu-177-pnt2002 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/lu-177-pnt2002/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "lu-177-pnt2002" ;
  schema:name "Lutetium-177 PNT2002"@en ;
  schema:alternateName "177Lu-PNT2002"@en, "177Lu-PSMA-I&T (POINT/Lantheus)"@en ;
  schema:description "A radioactive drug that homes in on a marker found on most prostate cancer cells, delivering radiation directly to the tumour, is being tested as a treatment for prostate cancer that has stopped responding to hormone therapy."@en ;
  schema:url <https://nuclide.cc/drugs/lu-177-pnt2002/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-and-point-biopharma-announce-positive-topline-results>, <https://investor.lantheus.com/node/14596/pdf>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC11745944/>, <https://clinicaltrials.gov/study/NCT04647526> ;
  nuclide:status "phase-3" ;
  nuclide:tag "PSMA", "radioligand therapy", "prostate cancer", "beta emitter", "phase 3" ;
  nuclide:modality "radioligand therapy" ;
  nuclide:related <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/lu177-psma-it/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:companies <https://nuclide.cc/companies/lantheus/>, <https://nuclide.cc/companies/point-biopharma/>, <https://nuclide.cc/companies/eli-lilly/> ;
  nuclide:trials <https://nuclide.cc/trials/splash/> .